The two leading statins in China have a a combined market of a billion dollars...China supports statins....Many of these Chinese statin patients would benefit from Vascepa also and hopefully China will be supportive of Vascepa as they have been with statins. The royalties accruing to Amarin from the sales of Vascepa(plus the 165 million dollars milestone fees) to be paid by Eddingpharm will help Amarin to supply the ROW....Its a win-win for everyone worldwide.
It could have been done with the U.S. markets alone if not the for the recent patent debacle, served up by the courts.
News 
Market Data 
Discover 
